The "Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global gastroesophageal reflux disease therapeutics market size is anticipated to reach USD 5.77 billion by 2030.
The market is projected to grow at a CAGR of 2.0% from 2025 to 2030. The growth is attributed to increasing prevalence of gastroesophageal reflux disease and other gastrointestinal diseases. Moreover, change in lifestyle and food habits, low success rates associated with GERD management devices and increasing demand for self-medication is further propelling the industry growth.
Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.
Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.
Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.
Gastroesophageal Reflux Disease Therapeutics Market Report Highlights
- Antacids segment dominated the gastroesophageal reflux disease treatment market in 2024 and is attributable to the rapid and quick relief offered by antacids, as they tend to counteract the acidity inside the stomach.
- Untreated condition owing to unnecessary condition that leads to additional medical issues is propelling the demand for proper therapeutics.
- Key players operating in the market are focusing on developing medications that helps in curbing the uncomfortable condition occurring through GERD.
- North America held the largest market share which can be attributed to the increasing technological advancements in diagnostics technologies that facilitate rehabilitation of disabled patients.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 100 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $5.11 billion |
| Forecasted Market Value (USD) by 2030 | $5.77 billion |
| Compound Annual Growth Rate | 2.0% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Gastroesophageal Reflux Disease Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.3. Business Environment Analysis
Chapter 4. Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Business Analysis
4.1. Drug Type Market Share, 2024 & 2030
4.2. Drug Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
4.4. Antacids
4.5. H2 Receptor Blockers
4.6. Proton Pump Inhibitors (PPIs)
4.7. Pro-kinetic Agents
Chapter 5. Gastroesophageal Reflux Disease Therapeutics Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2024 & 2030
5.2. Regional Market Dashboard
5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
5.4. North America
5.5. Europe
5.6. Asia Pacific
5.7. Latin America
5.8. MEA
Chapter 6. Competitive Landscape
6.1. Participant Overview
6.2. Company Market Position Analysis
6.3. Company Categorization
6.4. Strategy Mapping
6.5. Company Profiles
- AstraZeneca
- Eisai
- GSK
- Takeda Pharmaceutical Company
- Ironwood
- Johnson & Johnson Services
- SFJ Pharmaceuticals
- Sebela Pharmaceuticals
- Phathom Pharmaceuticals
- Camber Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/lt2k46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250117801910/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
